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Abbreviations and Acronyms 
CAD = coronary artery disease 
CABG = coronary artery bypass grafting 
IRA = infarct related artery 
PCI = percutaneous coronary intervention 
PPCI = primary percutaneous coronary intervention 
STEMI = ST-segment elevation myocardial infarction 
SVG = saphenous vein graft 
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What is Known: 
• There is limited data on outcomes of patients with previous coronary artery 
bypass grafting (CABG) presenting with ST-segment elevation myocardial 
infarction (STEMI) and undergoing primary percutaneous coronary 
intervention. 
• Many of the existing studies are limited because of small sample size. 
What the Study Adds: 
• This largest study to date found that patients with previous CABG are older, 
have more co-morbid conditions and adverse procedural variables. 
• Once differences are adjusted for, patients with previous CABG are not at 
increase risk of 30-day or longer term mortality. 
  4 
Abstract 
Background: There are limited data on outcomes of patients with previous coronary 
artery bypass grafting (CABG) presenting with ST-segment elevation myocardial 
infarction (STEMI) and undergoing primary percutaneous coronary intervention 
(PPCI). We report outcomes in STEMI patients undergoing PPCI with or without 
previous CABG surgery in a large real-world, all-comer population. 
Methods and Results: Clinical, demographic, procedural and outcomes data were 
collected for all patients undergoing PPCI in the UKEngland and Wales from January 
2007 to December 2012. All-cause mortality at 30-days and 1-year follow-up were 
evaluated in the whole and a propensity-matched cohort.  Of 79,295 STEMI patients 
studied, 2,658 (3.4%) patients had prior CABG, of whom 44% (n=1,168) underwent 
PPCI to native vessels and 56% (n=1,490) to bypass grafts. There were significant 
differences in the demographic, clinical and procedural characteristics of these 
groups. Patients with prior CABG (with primary PCI to native artery or graft) had 
higher mortality at 30-days (6.2% with PPCI to native artery, 6.1% with PPCI to 
bypass graft) than patients with no prior CABG (4.5%, p<0.001). However after risk 
factor adjustments there was no significant difference in outcomes. There were also 
no significant differences in 30-day mortality, in-hospital MACE, in-hospital stroke 
and in-hospital bleeding in the propensity-matched population. 
Conclusion: A prior history of CABG in patients presenting with STEMI and 
undergoing PPCI does not independently confer additional risk of mortality, although 
it is a marker of other high-risk features.  
Keywords: Coronary artery bypass graft, Saphenous vein graft, Percutaneous 
coronary intervention, Mortality, Cardiovascular disease 
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Introduction 
 Primary percutaneous coronary intervention (PPCI) is the gold standard of 
care for patients presenting with acute ST-elevation myocardial infarction (STEMI).1,2 
However, in patients with previous coronary artery bypass grafts (CABG) undergoing 
PPCI there is limited outcome data with many studies derived from small-scale 
registries or post-hoc analysis of selected small groups of patients with previous 
CABG from randomized trials.3-5 
 Patients with CABG tend to be older, have a higher incidence of co-
morbidities, poorer LV function and multi-vessel disease,6,7 that may contribute to 
poorer outcomes reported in the setting of PPCI in these patients.3,5,8 Even after 
adjustment for such differences adverse clinical characteristics, some studies report 
adverse outcomes in patients with previous CABG persist3,5,9 although others show 
either a modest10 or no difference in outcomes.8 Many of these studies in patients with 
prior CABG do not differentiate between outcomes if PPCI is performed on native 
vessel or in the saphenous vein graft (SVG)4,5,11 that may limit interpretation of 
outcomes.  
 Current STEMI guidelines do not specifically address the management of this 
complex group of patients in the PPCI setting, on account of the limited available 
evidence and limited outcome data in this cohort of patients, particularly from RCTs. 
This paucity of evidence may lead to delay or denial of PPCI therapy in patients with 
prior CABG presenting with STEMI.5,11 For example, in HORIZONS AMI only 84% 
of patients with previous CABG presenting with STEMI underwent PPCI whilst this 
was significantly higher at 93% in those patients with no prior CABG (P=0.0002).5 
Many of the previous studies have reported on outcomes in only a small number of 
patients, often with cohort sizes of around 1003-5,9 or have been derived from cohorts 
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in which contemporary pharmacotherapy was not used and PCI was undertaken using 
mainly bare metal stents or balloon angioplasty3,9 hence the applicability of outcomes 
reported to contemporary practice is unclear. We therefore study early (30-day) and 
late (1-year) outcomes of PPCI in patients with previous CABG in a large 
contemporary unselected national cohort from the database of the British 
Cardiovascular Intervention Society (BCIS) to define whether there are differences in 
outcomes between native vessel IRA and bypass graft IRA interventions in patients 
with previous CABG. 
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Methods 
Study design and data collection 
 This is a retrospective analysis of prospectively collected national data for all 
patients undergoing PPCI for STEMI in England and Wales from January 2007 to 
December 2012 in the BCIS database. BCIS records information on PCI practices in 
UK with data collection managed by the National Institute of Cardiovascular 
Outcomes Research (NICOR).12-14 The BCIS database contains 113 clinical, 
procedural and outcome variables with approximately 80,000 new records added each 
year. Using data from the Office of National Statistics, mortality was tracked for all 
patients in England and Wales using the patient's unique NHS number. Patients from 
Scotland and Northern Ireland were excluded due to the absence of the Office of 
National Statistics linked mortality data.  Institutional review board approval was not 
sought for this study as all data was anonymized and routinely collected as a part of a 
national audit. 
Variables and outcomes collected 
 We collected data on participants’ demographics, risk factors and 
comorbidities. In addition, data were also collected on the clinical state at the time of 
the intervention, left ventricular ejection fraction (LVEF), and all aspects of the 
interventional treatment and adjunctive pharmacology. 
 We evaluated all-cause mortality at 30-days and 1-year follow up. We also 
examined in-hospital major adverse cardiovascular events (MACE, defined as a 
composite of in-hospital mortality, in-hospital myocardial re-infarction and target 
vessel revascularization) and in-hospital major bleeding (defined as gastrointestinal 
bleed, intracerebral bleed, retroperitoneal hematoma, blood or platelet transfusion, or 
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an arterial access site complication requiring surgery). In-hospital stroke included 
ischemic stroke, hemorrhagic stroke or transient ischemic attack (TIA). 
 
Statistical methods 
 The study population was divided into three groups: i) no previous CABG, ii) 
prior CABG with PPCI to native coronary arteries, iii) Prior CABG with PPCI to 
bypass grafts. Patients with missing values for follow up time, sex and age were also 
excluded. The characteristics of patients were compared across the three groups of 
interest (pairwise) and also across inclusion and exclusion due to missing data. These 
comparisons were performed using Fisher's exact testschi-square tests for 
binary/categorical and ANOVA (ANalysis Of Variance) for continuous variables.  
 
 To be more inclusive with the data to analyze, account for data missing data 
and better protect against biases due to informative missing data mechanisms, we 
used multiple imputation with chained equations to impute data for all variables with 
missing information.  Age, sex, group of participant and study outcomes were 
registered as complete variables in the imputation models which were used to 
generate 10 datasets on which we ran the analyses (incomplete and imputed variables 
were: smoking status, diabetes, hypertension, hyperlipidemia, previous MI, previous 
stroke, peripheral vascular disease, renal disease, family history, radial access site, 
glycoprotein IIb/IIIa, shock, circulatory support, number of stents, thrombus 
aspiration, mechanical ventilation, femoral closure device and LVEF).  The STATA 
code and output of the imputations is shown in Supplementary Data 1.  
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 The risk of adverse outcomes by comparison group was estimated with 
univariable and multivariable logistic regressions. The former were not controlled for 
any covariates, while the latter were controlled (adjusted) for various patient 
characteristics. Covariates in the models included age, sex, smoking status, diabetes, 
hypertension, hyperlipidemia, previous MI, previous stroke, peripheral vascular 
disease, renal disease, family history, radial access site, glycoprotein IIb/IIIa, multi-
vessel PCI, shock, circulatory support, number of stents, thrombus aspiration, 
mechanical ventilation, femoral closure device, LVEF, PCI to left main stem, PCI to 
left anterior descending artery, and distal protection device.  
 
 We used multiple imputations with propensity score matching (mi 
estimate:teffects psmatch) to estimate the average treatment effect (ATE) to account 
for baseline difference across the groups of participants. We used two separate 
multiple imputation logistic regression models for which we calculated propensity 
scores for each group member: a) PCI to native vessel no graft (group 0) vs PCI to 
native vessel in patient with graft (group 1); and b) PCI to native vessel no graft 
(group 0) vs PCI to graft (group 2). The scores were then used to perform the 
matching and simple logistic regression were run (the only predictor being group 
membership) to obtain the ATE.  
 
 We performed additional Kaplan Meier survival analysis and Cox proportional 
hazards regression analysis for 30-day mortality and 1-year mortality by participant 
group.  Statistical analyses were performed using Stata version 13.1 (Stata Corp., 
Texas, USA).  
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RESULTS 
Study cohort 
 The study cohort consisted of 79,295 participants who had PPCI for STEMI in 
England and Wales and did not have missing values for death, follow-up, sex and age. 
The process of participant inclusion is shown in Figure 1. A total of 76,637 (96.6%) 
of patients had no previous CABG whereas 2,658 (3.4%) patients had prior CABG.  
Among patients with prior CABG, 44% (n=1,168) patients received PPCI to native 
vessels and 56% (n=1,490) underwent PPCI to bypass grafts. The mean follow up for 
these participants was 2.4±1.6 years and 86.5% of patients were followed-up for a 
minimum of one year (or until death if occurring within a year). 
Characteristics of participants 
 There were significant differences in the demographic, clinical and procedural 
characteristics of the three groups (Table 1). Patients with previous CABG were 
significantly older, and had a higher prevalence of diabetes, hypertension, peripheral 
vascular disease and previous MI or a stroke. The characteristics of those included in 
the study and those excluded are shown in Supplementary Table 1. 
Unadjusted outcomes 
 There was a significant difference in unadjusted mortality and in-hospital 
MACE among the three groups (Table 2). Figures 2a and b show the unadjusted 
Kaplan Meier survival curves for the 3 groups at 30 days (Figure 2a) and 1 year 
(Figure 2b) with significant differences in survival between the 3 groups noted (log-
rank test; P<0.001 and P<0.0001 for 30-day and 1-year mortality respectively). 
 Patients with prior CABG (with primary PCI to native artery or graft) had 
higher mortality at 30-days (6.2% with PPCI to native artery, 6.1% with PPCI to 
bypass graft) than patients with no prior CABG (4.5%, p<0.001). Similar 
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observations were recorded for 1-year mortality with the lowest rates observed in 
patients with no previous history of CABG (9.1%) with similar rates in patients with 
previous CABG and PCI to native vessels and bypass grafts (14.5% vs 11.9%; 
P<0.001).  
 In-hospital MACE rates, were higher in patients with prior CABG undergoing 
native vessel PCI (6.0%) compared with prior CABG undergoing PCI to a bypass 
graft (4.7%) or no prior CABG (4.2%). In contrast, in-hospital stroke rates and in-
hospital bleeding rates were similar across all three groups: 0.3% vs. 0.2% vs. 0.2%, 
respectively for stroke and 0.8% vs. 0.9% vs. 0.7%, respectively for in-hospital 
bleeding. 
Outcomes after risk-adjustment and imputations 
 The unadjusted, adjusted and imputed risk of mortality, in-hospital MACE, in-
hospital major bleeding and stroke outcomes are shown in Table 3.  In unadjusted 
univariate analysis the risk of 30-day mortality was significantly higher in PPCI 
undertaken in native coronary arteries in patients with previous CABG (OR 1.39 95% 
CI 1.10-1.77, p=0.007) and PPCI in bypass grafts (OR 1.38 95% CI 1.11-1.71, 
p=0.003) compared to PPCI in native coronary arteries (n=79,295). However 
following adjustments for baseline co-variates (in both the presence and absence of 
multiple imputations) there was no significant differences in outcomes for PPCI in 
native vessels in patients with CABG (OR 1.02 95% CI 0.77-1.34, p=0.89) but 
significant increase in 30-day mortality among patients with primary PCI to bypass 
grafts (OR 1.33 95% CI 1.03-1.71, p=0.026).  
Similarly, for in-hospital MACE, there were no significant differences in 
outcomes between PPCI undertaken in native coronary arteries in patients with 
previous CABG and PPCI in bypass grafts compared to PPCI in native coronary 
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arteries once differences in baseline co-variates were adjusted for PPCI to native 
arteries in patients with CABG (OR 0.95 95% CI 0.71-1.26, p=0.72) and PPCI to 
bypass grafts (OR 0.93 95% CI 0.70-1.22, p=0.58). There were no significant 
differences after adjustments with and without imputations and for all evaluations for 
risk of in-hospital stroke (OR 0.56 95% CI 0.14-2.30, p=0.42 and OR 0.69 95% CI 
0.22-2.21, p=0.53, respectively) and in-hospital bleeding (OR 0.95 95% CI 0.50-1.81, 
p=0.88 and OR 0.74 95% CI 0.39-1.43, p=0.38, respectively).  
Cox proportional hazards regression yielded similar results to those of 
unadjusted and adjusted logistic regressions for 30-day and 1 year mortality 
(Supplementary Table 2) 
 
Outcomes with propensity score matching 
 We performed a propensity-matching to correct for baseline characteristics 
(balance diagnostics for propensity model presented in Supplementary Table 3) and 
there were no differences in outcomes between patients with or without previous 
CABG or in patients with previous CABG where PCI was performed in either the 
native vessel or the graft (Table 4). 
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Discussion 
 This study from a national unselected cohort represents the largest analysis of 
patients with prior CABG undergoing PPCI in the literature. We show that patients 
with prior CABG are older, have more co-morbidities and adverse procedural 
characteristics but once these differences are adjusted for, patients with prior CABG 
have similar clinical outcomes following PPCI to patients without prior CABG. 
 Our unadjusted analysis shows that patients with a history of CABG have the 
highest mortality and MACE following PPCI when compared to patients with no 
CABG irrespective of whether the PCI is undertaken in the native coronary vessel or 
the bypass graft. Patients with a prior CABG have higher co-morbid burden and an 
overall higher adverse risk profile, which may contribute to poor outcomes observed. 
Indeed patients with previous CABG undergoing PCI to native vessels had 
significantly higher rates of cardiogenic shock presentation, mechanical ventilator 
support and circulatory support. Once adjustment is undertaken for such confounding 
risk factors, no statistically significant differences in clinical outcomes are seen 
between patients with or without prior CABG undergoing PPCI, irrespective of 
whether the PCI is performed in the native vessel or graft. 
 Previous studies have suggested that patients with prior CABG may have 
adverse outcomes when presenting with STEMI and treated with PPCI. These studies 
were either small-scale single center registries or post-hoc analysis of small numbers 
of patients derived from RCT. In the APEX-AMI (Assessment of Pexelizumab in 
Acute Myocardial Infarction) trial, patients with previous CABG (n=128) had 
increased 90-day mortality that remained significant after multivariable adjustment 
(HR 1.9, 95% CI 1.08 to 3.33, p = 0.025).3 In HORIZONS-AMI (Harmonizing 
Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial, 
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previous CABG (n=105) was associated with a higher incidence of MACE (36.4% vs 
21.4%, p <0.001) and mortality (11.2% vs 6.7%, p=0.08) at 3 years.5 In PAMI-2 
(Second Primary Angioplasty in Myocardial Infarction) trial, patients with previous 
CABG (n=58) were reported to have higher in-hospital (9.4% vs. 2.6%, p=0.02) and 
6-month (14.3% vs. 4.1%, p=0.001) mortality.9 A small registry from New York 
hospitals reported that patients with previous CABG presenting with STEMI (n=93) 
had higher unadjusted in-hospital mortality and MACE and on multivariate analysis, 
prior CABG (HR 3.40; 95% CI 1.15-10.00) was independently associated with in-
hospital mortality.4 In another study of 192 patients undergoing PPCI with a SVG 
culprit were shown to have higher unadjusted rates of mortality at 30 days and MACE 
at 1 year; although these effects were only modest after multivariable adjustment.10 A 
more recent analysis, from Kohl and colleagues, of 249 patients with prior CABG 
undergoing PPCI has suggested no significant differences in unadjusted rates of in-
hospital death (4.8% vs 5.9%, p=0.49), MACE at 30 days (6.8% vs 7.4%, p=0.76) 
(including stroke, recurrent infarction, recurrent ischemia, or death) or rates of 
hospital readmission at 30 days (1.7% vs 2.3%, p=0.82)  between PPCI in patients 
with previous CABG compared to those with no history of CABG although no 
adjustments were made for differences in baseline co-variates.8 Furthermore, no 
significant differences in mortality or MACE outcomes where observed in those 
patients with previous CABG who underwent PCI to either the graft or the native 
vessel.8  An overview of these studies is presented in Supplementary Table 4. 
 Our data suggests differences in the unadjusted clinical outcomes in patients 
with previous history of CABG, although once differences in baseline co-morbid 
conditions and procedural characteristics were adjusted for, outcomes were similar to 
those observed in patients without prior CABG. It has been well documented that 
  15 
patients with prior CABG presenting with STEMI are less likely to be offered PPCI 
than patients without prior CABG with similar observations recorded in patients with 
NSTEMI.15 In APEX-AMI, PCI was performed less frequently in patients with prior 
CABG compared with those with no history of CABG (78.9% vs. 93.9%, p<0.001) 3 
with similar findings reported by the HORIZON-AMI investigators and the PAMI-2 
study.9 Similarly, in older studies such as reports derived from the National Registry 
of Myocardial Infarction (NRMI)-3, patients presenting with STEMI with prior 
CABG were significantly less likely to receive PCI or thrombolysis than those 
without prior CABG.16 This practice may be influenced by the paucity of data in 
patients with prior CABG undergoing PPCI and the perceived lack of efficacy of 
PPCI in these patients. 
 Previous reports have debated whether the outcomes are different if PPCI is 
performed on native vessel or SVG in patients with previous CABG.3,5,17-19 Although 
PPCI to vein grafts is often more technically challenging and complex, our data show 
no significant difference in adjusted outcomes in patients with prior CABG 
undergoing native or bypass graft PPCI.  
 Our analysis has several strengths. The BCIS dataset includes an almost 
complete collection of all PCI procedures performed in the United Kingdom 
representing unselected real-world experience including high-risk patient often 
excluded from RCTs and represents the largest analysis of primary PCI for STEMI 
patients with previous CABG to be reported. 
 We recognize that this study has several potential limitations. Firstly, whilst 
mortality tracking within the United Kingdom is very robust, all other outcomes and 
complications are self-reported without formal adjudication. Therefore, the analysis is 
potentially vulnerable to reporting biases, and complications may be under-reported. 
  16 
Second, whilst this analysis reports on outcomes in patients undergoing PPCI, 
previous studies have suggested that PPCI is less likely to be performed when the 
infarct-related vessel was a bypass graft rather than a native coronary artery9 which 
may contribute to selection/referral biases in our cohort. The BCIS dataset does not 
record information regarding patients who presented with STEMI but were medically 
managed and so cannot exclude significant referral or selection bias particularly for 
those patients with previous CABG similar to other studies.3, 5, 16 Third, our analysis 
report outcomes derived from grafts as the BCIS dataset does not differentiate 
between venous and arterial grafts. Previous data derived from the National 
Cardiovascular Data Registry (NCDR) CathPCI registry suggests that arterial grafts 
represented 2.5% of all PCI procedures undertaken to bypass grafts in the United 
States although this did not report practice or outcomes in a primary PCI cohort 
specifically.17  
In conclusion, our data demonstrate that after adjusting for co-morbidities, 
PPCI for STEMI results in similar outcomes for patients who have had previous 
CABG (either in a native vessel or a bypass graft) when compared to those who have 
not had previous CABG.  PPCI for STEMI should be the primary treatment strategy 
for patients who have had previous CABG. 
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Table 1: Baseline characteristics of patients 
Variable Group 1 (n=76,637) Group 2 (n=1,168) Group 3 (n=1,490) 
Age 63.3 (±13.1) 67.1 (±11.5) 67.3 (±11.5) 
Female sex 19,846/76,637 (25.9%) 216/1,168 (18.5%) 301/1,490 (20.2%) 
Smoking 46,429/68,505 (67.8%) 708/999 (70.9%) 855/1,285 (66.5%) 
Diabetes 9,733/73,562 (13.2%) 269/1,081 (24.9%) 279/1,430 (19.5%) 
Hypertension 29,757/75,483 (39.4%) 661/1,154 (57.3%) 750/1,470 (51.0%) 
Hyperlipidemia 29,368/75,483 (38.9%) 698/1,154 (60.5%) 727/1,470 (49.5%) 
Previous MI 8,202/70,196 (11.7%) 555/1,050 (52.9%) 638/1,370 (46.6%) 
Previous CVA 2,670/75,483 (3.5%) 71/1,154 (6.2%) 85/1,470 (5.8%) 
Peripheral vascular 
disease 
2,329/75,483 (3.1%) 78/1,154 (6.8%) 93/1,470 (6.3%) 
Previous renal 
disease 
1,121/70,583 (1.6%) 43/1,023 (4.2%) 48/1,382 (3.5%) 
LVEF 
Good 
Moderate 
Poor 
 
12,535 (53.0%) 
8,701 (36.8%) 
2,401 (10.2%) 
 
176 (48.4%) 
127 (34.9%) 
61 (16.8%) 
 
206 (46.6%) 
187 (42.3%) 
49 (11.1%) 
Family history of 
heart disease 
24,220/65,018 (37.3%) 426/959 (44.4%) 489/1,238 (39.5%) 
Access site 
Femoral 
Radial 
 
36,849 (50.4%) 
36,272 (49.6%) 
 
846 (76.9%) 
254 (23.1%) 
 
968 (69.3%) 
428 (30.7%) 
Glycoprotein 
IIb/IIIa inhibitor 
36,831/67,562 (54.5%) 478/1,041 (45.9%) 716/1,341 (53.4%) 
Target vessel 
LAD 
Left main 
Circumflex 
Right coronary 
artery 
Graft 
 
34,262 (44.7%) 
1,221 (1.6%) 
12,094  (15.8%) 
33,222 (43.4%)  
0 (0%) 
 
280 (24.0%) 
119 (10.2%) 
264 (22.6%) 
515 (44.1%) 
0 (0%) 
 
37 (2.5%) 
10 (0.7%) 
44 (3.0%) 
70 (4.7%) 
1,490 (100%) 
Multivessel PCI 8,084/76,637 (10.6%) 101/1,168 (8.7%) 150/1,490 (10.1%) 
Cardiogenic shock 4,396/76,126 (5.8%) 93/1,164 (8.0%) 79/1,478 (5.4%) 
Circulatory support 3,426/71,346 (4.8%) 81/1,101 (7.4%) 80/1,417 (5.7%) 
DES use 42,236/73,837 (57.2%) 618/1,127 (54.8%) 709/1,418 (50.0%) 
Number of stents 
0 
1 
2 
≥3 
 
31,601 (42.8%) 
26,290 (35.6%) 
11,561 (15.7%) 
4,385 (5.9%) 
 
509 (45.1%) 
368 (32.7%) 
171 (15.2%) 
79 (7.0%) 
 
709 (50.0%) 
396 (27.9%) 
213 (15.0%) 
100 (7.1%) 
Thrombus 
aspiration 
35,550/72,525 (49.0%) 394/1,113 (35.4%) 648/1,443 (44.9%) 
Mechanical 
ventilator support 
2,166/67,023 (3.2%) 48/1,028 (4.7%) 51/1,274 (4.0%) 
Femoral closure 
device 
24,893/71,187 (35.0%) 500/1,090 (45.9%) 564/1,428 (39.5%) 
Use of distal 
protection device 
278/70,259 (0.4%) 17/1,076 (1.6%) 132/1,398 (9.4%) 
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Symptom to 
balloon time (hrs) 
2.3±2.0 2.6±2.2 2.4±1.8 
Group 1: Primary PCI in native coronary arteries 
Group 2: Primary PCI in native coronary arteries in patient with CABG 
Group 3: Primary PCI in bypass grafts 
MI = myocardial infarction, CVA = cerebrovascular accident, LVEF = left ventricular ejection 
fraction, LAD = left anterior descending, DES = drug eluting stent 
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Table 2: Unadjusted outcomes 
Outcome Group 1 (n=76,637) Group 2 (n=1,168) Group 3 (n=1,490) p-value 
Group 1 vs 
Group 2* 
p-value 
Group 1 vs 
Group 3*  
p-value 
Group 2 vs 
Group 3* 
In-hospital mortality 2,465/73,677 (3.4%) 55/1,080 (5.1%) 53/1,442 (3.7%) 0.003 0.46 0.091 
30-day mortality 3,447/76,637 (4.5%) 72/1,168 (6.2%) 91/1,490 (6.1%) 0.009 0.005 1.00 
1-year mortality 6,026/66,217 (9.1%) 147/1,014 (14.5%) 158/1,329 (11.9%) <0.001 0.001 0.072 
In-hospital MACE 3,108/74,369 (4.2%) 65/1,089 (6.0%) 69/1,455 (4.7%) 0.006 0.29 0.18 
In-hospital re-infarction 264/74,319 (0.4%) 4/1,084 (0.4%) 12/1,454 (0.8%) 0.80 0.012 - 
In-hospital re-intervention 447/74,319 (0.6%) 6/1,084 (0.6%) 8/1,454 (0.6%) 1.00 1.00 - 
In-hospital emergency 
CABG 
69/74,319 (0.1%) 2/1,084 (0.2%) 1/1,454 (0.1%) 0.27 1.00 - 
In-hospital stroke 215/74,319 (0.3%) 2/1,084 (0.2%) 3/1,454 (0.2%) 0.78 0.80 - 
In-hospital embolic stroke 129/74,319 (0.2%) 2/1,084 (0.2%) 3/1,454 (0.2%) 0.71 0.74 - 
In-hospital TIA 53/74,319 (0.1%) 0/1,084 (0%) 0/1,454 (0%) 1.00 0.63 - 
In-hospital hemorrhagic 
stroke 
34/74,319 (0.1%) 0/1,084 (0%) 0/1,454 (0%) 1.00 1.00 - 
In-hospital bleeding 578/74,320 (0.8%) 10/1,084 (0.9%) 10/1,454 (0.7%) 0.60 0.88 0.51 
Group 1: Primary PCI in native coronary arteries 
Group 2: Primary PCI in native coronary arteries in patient with CABG 
Group 3: Primary PCI in bypass grafts 
MACE = major adverse cardiovascular events, CABG = coronary artery bypass graft, TIA = transient ischemic attack 
*P-value determined by Fisher's exact test 
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Table 3: Risk of adverse outcomes with unadjusted and adjusted results 
Variable Group 1: 
Primary PCI 
in native 
coronary 
arteries 
Group 2: Primary PCI in 
native coronary arteries 
in patient with CABG  
Group 3: Primary PCI in 
bypass grafts  
In-hospital mortality 
Unadjusted (n=76,199) 
Adjusted† (n=76,199) 
 
Reference 
Reference 
 
1.55 (1.18-2.04), p=0.002 
1.07 (0.78-1.48), p=0.66 
 
1.10 (0.84-1.45), p=0.49 
0.99 (0.72-1.37), p=0.96 
30 day mortality 
Unadjusted (n=79,295) 
Adjusted† (n=79,295) 
 
Reference 
Reference 
 
1.39 (1.10-1.77), p=0.007 
1.02 (0.77-1.34), p=0.89 
 
1.38 (1.11-1.71), p=0.003 
1.33 (1.03-1.71), p=0.028 
1 year mortality 
Unadjusted (n=68,560) 
Adjusted† (n=68,560) 
 
Reference 
Reference 
 
1.69 (1.42-2.02), p<0.001 
1.17 (0.95-1.43), p=0.15 
 
1.35 (1.14-1.59), p=0.001 
1.16 (0.95-1.41), p=0.14 
In-hospital MACE 
Unadjusted (n=76,913) 
Adjusted† (n=76,913) 
 
Reference 
Reference 
 
1.46 (1.13-1.87), p=0.004 
0.95 (0.71-1.26), p=0.72 
 
1.14 (0.89-1.46), p=0.29 
0.93 (0.70-1.22), p=0.58 
In-hospital Stroke 
Unadjusted (n=76,857) 
Adjusted† (n=76,857) 
 
Reference 
Reference 
 
0.64 (0.16-2.57), p=0.53 
0.56 (0.14-2.30), p=0.42 
 
0.71 (0.23-2.23), p=0.56 
0.69 (0.22-2.21), p=0.53 
In-hospital Bleeding 
Unadjusted  (n=76,858) 
Adjusted† (n=76,858) 
 
Reference 
Reference 
 
1.19 (0.63-2.23), p=0.59 
0.95 (0.50-1.81), p=0.88 
 
0.88 (0.47-1.65), p=0.70 
0.74 (0.39-1.43), p=0.38 
†Adjusted for age, sex, smoking status, diabetes, hypertension, hyperlipidemia, previous 
myocardial infarction, previous stroke, peripheral vascular disease, renal disease, family 
history, radial access site, glycoprotein IIb/IIIa inhibitor, multivessel, PCI to left anterior 
descending artery, PCI to left main artery, shock, circulatory support, no of stents, thrombus 
aspiration, ventilation, femoral closure device, distal protection device, symptom to balloon 
with 10 imputations for all variables. 
  23 
Table 4: Propensity score matched analysis with average treatment effects 
Analysis Group Coefficient 95% CI p-value 
In-hospital 
mortality 
Group 1: Primary PCI in native 
coronary arteries 
Reference    
Group 2: Primary PCI in native 
coronary arteries in patient with 
CABG (n=72,068) 
0.0143 -0.0163 0.0448 0.36 
Group 3: Primary PCI in bypass grafts 
(n=72,407) 
0.1505 -0.2237 0.5247 0.42 
30 day 
mortality 
Group 1: Primary PCI in native 
coronary arteries 
Reference    
Group 2: Primary PCI in native 
coronary arteries in patient with 
CABG (n=74,964) 
0.0121 -0.0212 0.0454 0.47 
Group 3: Primary PCI in bypass grafts 
(n=75,255) 
0.1524 -0.2252 0.5300 0.42 
1 year  
Mortality 
Group 1: Primary PCI in native 
coronary arteries 
Reference    
Group 2: Primary PCI in native 
coronary arteries in patient with 
CABG (n=64,756) 
0.2689 -0.0129 0.0666 0.19 
Group 3: Primary PCI in bypass grafts 
(n=65,039) 
0.1450 -0.2877 0.5778 0.50 
In-hospital 
MACE 
Group 1: Primary PCI in native 
coronary arteries 
Reference    
Group 2: Primary PCI in native 
coronary arteries in patient with 
CABG (n=72,735) 
0.0135 -0.0176 0.0445 0.39 
Group 3: Primary PCI in bypass grafts 
(n=73,078) 
0.1494 -0.2371 0.5359 0.44 
In-hospital 
stroke 
Group 1: Primary PCI in native 
coronary arteries 
Reference    
Group 2: Primary PCI in native 
coronary arteries in patient with 
CABG (n=72,683) 
-0.0011 -0.0057 0.0035 0.63 
Group 3: Primary PCI in bypass grafts 
(n=73,030) 
-0.0014 -0.0043 0.0015 0.33 
In-hospital 
bleeding 
Group 1: Primary PCI in native 
coronary arteries 
Reference    
Group 2: Primary PCI in native 
coronary arteries in patient with 
CABG (n=72,684) 
-0.0025 -0.0117 0.0067 0.59 
Group 3: Primary PCI in bypass grafts  
(n=73,031) 
-0.0061 -0.0084 -
0.0038 
<0.001 
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Figure 1: Flow chart of participant inclusion  
 
 
 
 
 
Patients with primary PCI in 
England and Wales 
n=80,516. 
Patients with missing data 
for age n=2, sex n=235, and 
mortality follow up 1,199. 
Total cohort n=79,295: PCI 
to native vessel no graft 
(n=76,637), PCI to native 
vessel in patient with graft 
(n=1,168), PCI to graft 
(n=1,490). 
  25 
Figure 2: Kaplan-Meier survival curves at 30 days and 1 year 
A) 
 
Follow up Day 0 Day 10 Day 20 Day 30 
Number at risk in PCI to 
native coronary arteries 
75,932 74,097 73,440 73,190 
Number at risk in PCI to 
native coronary arteries in 
patient with CABG 
1,154 1,115 1,103 1,096 
Number at risk in PCI to 
bypass graft 
1,473 1,425 1,410 1,399 
 
Log-rank test p<0.001 
B) 
  26 
 
Log-rank test p<0.001 
Follow up Day 0 Day 90 Day 180 Day 270 Day 365 
Number at risk in PCI to 
native coronary arteries 
75,932 72,373 70,513 65,259 60,456 
Number at risk in PCI to 
native coronary arteries in 
patient with CABG 
1,154 1,078 1,041 953 871 
Number at risk in PCI to 
bypass graft 
1,473 1,378 1,341 1,258 1,177 
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Supplementary Table 1: Missing data table 
Variable Data available for 
imputations 
Missing data or 
excluded 
Age 79,295 1,221 
Female 79,295 1,221 
Smoking 70,789 9,727 
Diabetes 76,073 4,443 
Hypertension 78,107 2,409 
Hyperlipidemia 78,107 2,409 
Previous MI 72,616 7,900 
Previous CVA 78,107 2,409 
Peripheral vascular disease 78,107 2,409 
Previous renal disease 72,988 7,528 
LVEF 24,443 56,073 
Family history of heart 
disease 
67,215 13,301 
Access site 75,617 4,899 
Glycoprotein IIb/IIIa 
inhibitor 
69,944 10,572 
Target vessel 
LAD 
Left main 
Circumflex 
Right coronary artery 
Graft 
 
79,205 
79,205 
79,205 
79,205 
79,205 
 
1,311 
1,311 
1,311 
1,311 
1,311 
Multivessel 79,295 1,221 
Thrombectomy device 72,599 7,917 
Cardiogenic shock 78,768 1,748 
Circulatory support 73,864 6,652 
DES use 76,382 4,134 
Number of stents 76,382 4,134 
Thrombus aspiration 75,081 5,435 
Ventilatory support 69,325 11,191 
Femoral closure device 73,705 6,811 
Use of distal protection 
device 
72,733 7,783 
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Supplementary Table 2: Logistic regression and Cox proportional hazards analysis for 30-day 
mortality and 1-year mortality 
 
Outcome Logistic regression odds ratio 
for outcome (95% CI), p-value 
Cox proportional hazard ratio 
for outcome (95% CI), p-value 
Unadjusted 30 day mortality 
Group 1 
Group 2 
Group 3 
 
1.00 (ref) 
1.39 (1.10-1.77), p=0.007 
1.38 (1.11-1.71), p=0.003 
 
1.00 (ref) 
1.40 (1.08-1.82), p=0.011 
1.40 (1.11-1.76), p=0.004 
Adjusted 30 day mortality* 
Group 1 
Group 2 
Group 3 
 
1.00 (ref) 
1.02 (0.77-1.34), p=0.89 
1.33 (1.03-1.70), p=0.028 
 
1.00 (ref) 
1.07 (0.81-1.40), p=0.65 
1.41 (1.10-1.79), p=0.006 
Unadjusted 1-year mortality 
Group 1 
Group 2 
Group 3 
 
1.00 (ref) 
1.69 (1.42-2.02), p<0.001 
1.35 (1.14-1.59), p=0.001 
 
1.00 (ref) 
1.67 (1.41-1.98), p<0.001 
1.34 (1.14-1.59), p=0.001 
Adjusted 1-year mortality* 
Group 1 
Group 2 
Group 3 
 
1.00 (ref) 
1.17 (0.95-1.43), p=0.15 
1.16 (0.95-1.41), p=0.14 
 
1.00 (ref) 
1.11 (0.92-1.33), p=0.28 
1.21 (1.01-1.44), p=0.035 
Group 1: Primary PCI in native coronary arteries, Group 2: Primary PCI in native coronary 
arteries in patient with CABG, Group 3: Primary PCI in bypass grafts 
*Adjusted for age, sex, smoking status, hypertension, hyperlipidemia, diabetes mellitus, 
previous stroke, peripheral vascular disease, renal disease, family history, access site, use of 
glycoprotein IIb/IIIa inhibitor, multivessel PCI, femoral closure device, cardiogenic shock, use 
of circulatory support, number of stents, use of thrombectomy device, receipt of ventilation, 
LV ejection fraction, embolic protection device, left main stem disease, left anterior 
descending disease, balloon time. 
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Supplementary Table 3: Balance diagnostics for propensity model 
Groups  Mean (SD) Median (IQR) 
Group 1: Primary PCI 
in native coronary 
arteries vs Group 2: 
Primary PCI in native 
coronary arteries in 
patient with CABG 
Case 0.9850 
(0.0314) 
0.9939 
(0.9865, 0.9969) 
Control 0.9850 
(0.0.314) 
0.9939 
(0.9865, 0.9969) 
Abs(Case-
Control) 
0.00005  
(0.00036) 
0.00002 
(7*10-6, 0.00004) 
Group 1: Primary PCI 
in native coronary 
arteries vs Group 3: 
Primary PCI in 
bypass grafts 
Case 0.9811  
(0.0440) 
0.9907  
(0.9812, 0.9995) 
Control 0.9811  
(0.0439) 
0.9907 
(0.9811, 0.9994) 
Abs(Case-
Control) 
0.0001 
(0.0007) 
0.00004 
(0.00001, 0.00013) 
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Supplementary Table 4: Summary of the studies evaluating mortality and major adverse cardiovascular events in patient with and without prior 
coronary artery bypass graft who present with STEMI or acute myocardial infarction. 
Study ID No. of participants Unadjusted results Adjusted results 
Bench 2013 1,649 PPCI in patient with 
STEMI. 93 with prior CABG. 
Prior CABG vs no revascularization: 
MACCE 6.5% vs 2.7%, in-hospital death 
6.5% vs 2.2%. 
Prior CABG was not associated with 
increased MACE (OR 1.77 95%CI 0.67-
4.70) but was associated with increased in-
hospital mortality (OR 3.40 95%CI 1.15-
10.00). 
Gaglia 2011 4,192 PCI in patient with acute 
myocardial infarction. 192 with 
prior CABG. 
Saphenous vein graft versus native 
vessel: in-hospital cardiac mortality 6.6% 
vs 3.3% and overall mortality at 30 days 
14.3% vs 8.4%. 1 year MACE 36.8% vs 
24.5%, 1 year mortality 29.8% vs 16.4%. 
Prior CABG and 30 day mortality HR 2.13 
95% CI 1.06-4.26.  1 year MACE HR 1.87 
95% CI 1.22-2.87. 
Kohl 2014 3,542 patients with STEMI. 
249 had prior CABG. 
Previous CABG vs no previous CABG 
and outcomes at 30 days: death 4.8% vs 
5.9%, p=0.49, MACE 6.8% vs 7.4%, 
p=0.76. Outcomes at 1 year: death 10.8% 
vs 9.1%, p=0.36, MACE 15.7% vs 
14.2%, p=0.12.   
No adjusted results. 
Nikolsky 
2013 
3,599 patients with STEMI. 
105 had prior CABG. 
Previous CABG and no previous CABG 
at outcomes at 30 days: death 3.8% vs 
2.6%, MACE 8.6% vs 5.4%. 
Prior CABG was not a predictor of 3 year 
mortality HR 0.37 95% CI 0.10-1.34, 3 year 
MACE HR 0.81 95% CI 0.42-1.55. 
Stone 2000 1,100 patients with acute 
myocardial infarction. 58 had 
prior CABG. 
Previous CABG and no previous CABG 
and in-hospital outcomes: death 6.9% vs 
2.6%, MACE 15.5% vs 19.4%. 
No adjusted results. 
Welsh 2010 5,745 patients with STEMI. 
128 had prior CABG. 
Previous CABG vs no previous CABG 
and 90 day outcomes: death 11.9% vs 
4.6%, death/congestive heart 
failure/shock 16.4% vs 10.1%. 
Prior CABG was associated with 90-day 
death HR 1.90 95% CI 1.08-3.33 but not 
death/congestive heart failure/shock HR 
1.06 95% CI 0.66-1.70. 
 
  31 
Supplementary Data 1: Stata code for multiple imputations 
mi set mlong 
 
mi register imputed balloontime shock mi dm gpi circsupp femclose smoking fh hchol htn pvd 
cva ventilate fem0rad1 lvef /*device*/ renal stents des emboli thromb 
(66636 m=0 obs. now marked as incomplete) 
 
 mi register regular group age sex multivessel mfu inhospdeath dead30 dead365 dead mace 
cvableed cvaembolic tia emergcabg reintervention reinfarction bleed stroke lmain lad cx rca 
graft 
 
mi impute chained (truncreg) balloontime (logit) shock mi dm gpi circsupp femclose smoking 
fh hchol htn pvd cva ventilate fem0rad1 /*device*/ renal emboli thromb (mlogit) stents (ologit) 
lvef = age i.sex i.group i.multivessel mfu, add(10) /*noisily*/ augment report chaindots  
 
Checking equations: 
 -- above applies to specification (logit ) shock = age i.sex i.group i.multivessel mfu 
 -- above applies to specification (logit ) hchol = age i.sex i.group i.multivessel mfu 
 -- above applies to specification (logit ) htn = age i.sex i.group i.multivessel mfu 
 -- above applies to specification (logit ) pvd = age i.sex i.group i.multivessel mfu 
 -- above applies to specification (logit ) cva = age i.sex i.group i.multivessel mfu 
 -- above applies to specification (mlogit ) stents = age i.sex i.group i.multivessel mfu 
 -- above applies to specification (logit ) dm = age i.sex i.group i.multivessel mfu 
 -- above applies to specification (logit ) fem0rad1 = age i.sex i.group i.multivessel mfu 
 -- above applies to specification (logit ) thromb = age i.sex i.group i.multivessel mfu 
 -- above applies to specification (logit ) circsupp = age i.sex i.group i.multivessel mfu 
 -- above applies to specification (logit ) femclose = age i.sex i.group i.multivessel mfu 
 -- above applies to specification (logit ) renal = age i.sex i.group i.multivessel mfu 
 -- above applies to specification (logit ) emboli = age i.sex i.group i.multivessel mfu 
 -- above applies to specification (logit ) mi = age i.sex i.group i.multivessel mfu 
 -- above applies to specification (logit ) smoking = age i.sex i.group i.multivessel mfu 
 -- above applies to specification (logit ) gpi = age i.sex i.group i.multivessel mfu 
 -- above applies to specification (logit ) ventilate = age i.sex i.group i.multivessel mfu 
 -- above applies to specification (logit ) fh = age i.sex i.group i.multivessel mfu 
 -- above applies to specification (truncreg ) balloontime = age i.sex i.group i.multivessel mfu 
 -- above applies to specification (ologit ) lvef = age i.sex i.group i.multivessel mfu 
 
Conditional models: 
 
shock: logit shock i.hchol i.htn i.pvd i.cva i.stents i.dm i.fem0rad1 i.thromb i.circsupp 
i.femclose i.renal i.emboli i.mi i.smoking i.gpi i.ventilate i.fh balloontime i.lvef age i.sex 
i.group i.multivessel mfu, augment 
 
 hchol: logit hchol i.shock i.htn i.pvd i.cva i.stents i.dm i.fem0rad1 i.thromb i.circsupp 
i.femclose i.renal i.emboli i.mi i.smoking i.gpi i.ventilate i.fh balloontime i.lvef age i.sex 
i.group i.multivessel mfu , augment 
 
htn: logit htn i.shock i.hchol i.pvd i.cva i.stents i.dm i.fem0rad1 i.thromb i.circsupp i.femclose 
i.renal i.emboli i.mi i.smoking i.gpi i.ventilate i.fh balloontime i.lvef age i.sex i.group 
i.multivessel mfu , augment 
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pvd: logit pvd i.shock i.hchol i.htn i.cva i.stents i.dm i.fem0rad1 i.thromb i.circsupp i.femclose 
i.renal i.emboli i.mi i.smoking i.gpi i.ventilate i.fh balloontime i.lvef age i.sex i.group 
i.multivessel mfu , augment 
 
cva: logit cva i.shock i.hchol i.htn i.pvd i.stents i.dm i.fem0rad1 i.thromb i.circsupp i.femclose 
i.renal i.emboli i.mi i.smoking i.gpi i.ventilate i.fh balloontime i.lvef age i.sex i.group 
i.multivessel mfu , augment 
 
stents: mlogit stents i.shock i.hchol i.htn i.pvd i.cva i.dm i.fem0rad1 i.thromb i.circsupp 
i.femclose i.renal i.emboli i.mi i.smoking i.gpi i.ventilate i.fh balloontime i.lvef age i.sex 
i.group i.multivessel mfu , augment 
 
dm: logit dm i.shock i.hchol i.htn i.pvd i.cva i.stents i.fem0rad1 i.thromb i.circsupp i.femclose 
i.renal i.emboli i.mi i.smoking i.gpi i.ventilate i.fh balloontime i.lvef age i.sex i.group 
i.multivessel mfu , augment 
 
fem0rad1: logit fem0rad1 i.shock i.hchol i.htn i.pvd i.cva i.stents i.dm i.thromb i.circsupp 
i.femclose i.renal i.emboli i.mi i.smoking i.gpi i.ventilate i.fh balloontime i.lvef age i.sex 
i.group i.multivessel mfu , augment 
 
thromb: logit thromb i.shock i.hchol i.htn i.pvd i.cva i.stents i.dm i.fem0rad1 i.circsupp 
i.femclose i.renal i.emboli i.mi i.smoking i.gpi i.ventilate i.fh balloontime i.lvef age i.sex 
i.group i.multivessel mfu , augment 
 
circsupp: logit circsupp i.shock i.hchol i.htn i.pvd i.cva i.stents i.dm i.fem0rad1 i.thromb 
i.femclose i.renal i.emboli i.mi i.smoking i.gpi i.ventilate i.fh balloontime i.lvef age i.sex 
i.group i.multivessel mfu , augment 
 
femclose: logit femclose i.shock i.hchol i.htn i.pvd i.cva i.stents i.dm i.fem0rad1 i.thromb 
i.circsupp i.renal i.emboli i.mi i.smoking i.gpi i.ventilate i.fh balloontime i.lvef age i.sex 
i.group i.multivessel mfu , augment 
 
renal: logit renal i.shock i.hchol i.htn i.pvd i.cva i.stents i.dm i.fem0rad1 i.thromb i.circsupp 
i.femclose i.emboli i.mi i.smoking i.gpi i.ventilate i.fh balloontime i.lvef age i.sex i.group 
i.multivessel mfu , augment 
 
emboli: logit emboli i.shock i.hchol i.htn i.pvd i.cva i.stents i.dm i.fem0rad1 i.thromb 
i.circsupp i.femclose i.renal i.mi i.smoking i.gpi i.ventilate i.fh balloontime i.lvef age i.sex 
i.group i.multivessel mfu , augment 
 
mi: logit mi i.shock i.hchol i.htn i.pvd i.cva i.stents i.dm i.fem0rad1 i.thromb i.circsupp 
i.femclose i.renal i.emboli i.smoking i.gpi i.ventilate i.fh balloontime i.lvef age i.sex i.group  
i.multivessel mfu , augment 
 
smoking: logit smoking i.shock i.hchol i.htn i.pvd i.cva i.stents i.dm i.fem0rad1 i.thromb 
i.circsupp i.femclose i.renal i.emboli i.mi i.gpi i.ventilate i.fh balloontime i.lvef age i.sex 
i.group i.multivessel mfu , augment 
 
gpi: logit gpi i.shock i.hchol i.htn i.pvd i.cva i.stents i.dm i.fem0rad1 i.thromb i.circsupp 
i.femclose i.renal i.emboli i.mi i.smoking i.ventilate i.fh balloontime i.lvef age i.sex i.group 
i.multivessel mfu , augment 
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ventilate: logit ventilate i.shock i.hchol i.htn i.pvd i.cva i.stents i.dm i.fem0rad1 i.thromb 
i.circsupp i.femclose i.renal i.emboli i.mi i.smoking i.gpi i.fh balloontime i.lvef age i.sex 
i.group i.multivessel mfu , augment 
 
fh: logit fh i.shock i.hchol i.htn i.pvd i.cva i.stents i.dm i.fem0rad1 i.thromb i.circsupp 
i.femclose i.renal i.emboli i.mi i.smoking i.gpi i.ventilate balloontime i.lvef age i.sex i.group 
i.multivessel mfu , augment 
 
balloontime: truncreg balloontime i.shock i.hchol i.htn i.pvd i.cva i.stents i.dm i.fem0rad1 
i.thromb i.circsupp i.femclose i.renal i.emboli i.mi i.smoking i.gpi i.ventilate i.fh i.lvef age 
i.sex i.group i.multivessel mfu 
 
lvef: ologit lvef i.shock i.hchol i.htn i.pvd i.cva i.stents i.dm i.fem0rad1 i.thromb i.circsupp 
i.femclose i.renal i.emboli i.mi i.smoking i.gpi i.ventilate i.fh balloontime age i.sex i.group 
i.multivessel mfu , augment 
 
Performing chained iterations: 
  imputing m=1: burn-in 10 .......... done 
  imputing m=2: burn-in 10 .......... done 
  imputing m=3: burn-in 10 .......... done 
  imputing m=4: burn-in 10 .......... done 
  imputing m=5: burn-in 10 .......... done 
  imputing m=6: burn-in 10 .......... done 
  imputing m=7: burn-in 10 .......... done 
  imputing m=8: burn-in 10 .......... done 
  imputing m=9: burn-in 10 .......... done 
  imputing m=10: burn-in 10 .......... done 
 
Multivariate imputation                      Imputations = 10 
Chained equations                                  added =  10 
Imputed: m=1 through m=10                 updated = 0 
 
Initialization: monotone                      Iterations =  100 
                                                  burn-in =       10 
 
       balloontime: truncated regression 
             shock: logistic regression 
                mi: logistic regression 
                dm: logistic regression 
               gpi: logistic regression 
          circsupp: logistic regression 
          femclose: logistic regression 
           smoking: logistic regression 
                fh: logistic regression 
             hchol: logistic regression 
               htn: logistic regression 
               pvd: logistic regression 
               cva: logistic regression 
         ventilate: logistic regression 
          fem0rad1: logistic regression 
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             renal: logistic regression 
            emboli: logistic regression 
            thromb: logistic regression 
            stents: multinomial logistic regression 
              lvef: ordered logistic regression 
 
------------------------------------------------------------------ 
                   |               Observations per m              
                   |---------------------------------------------- 
          Variable |   Complete   Incomplete   Imputed |     Total 
-------------------+-----------------------------------+---------- 
       balloontime |      65492        13803     13803 |     79295 
             shock |      78768          527       527 |     79295 
                mi |      72616         6679      6679 |     79295 
                dm |      76073         3222      3222 |     79295 
               gpi |      69944         9351      9351 |     79295 
          circsupp |      73864         5431      5431 |     79295 
          femclose |      73705         5590      5590 |     79295 
           smoking |      70789         8506      8506 |     79295 
                fh |      67215        12080     12080 |     79295 
             hchol |      78107         1188      1188 |     79295 
               htn |      78107         1188      1188 |     79295 
               pvd |      78107         1188      1188 |     79295 
               cva |      78107         1188      1188 |     79295 
         ventilate |      69325         9970      9970 |     79295 
          fem0rad1 |      75617         3678      3678 |     79295 
             renal |      72988         6307      6307 |     79295 
            emboli |      72733         6562      6562 |     79295 
            thromb |      75081         4214      4214 |     79295 
            stents |      76382         2913      2913 |     79295 
              lvef |      24443        54852     54852 |     79295 
------------------------------------------------------------------ 
(complete + incomplete = total; imputed is the minimum across m 
 of the number of filled-in observations.) 
 
 
